LPA/LPAR signaling drives temporomandibular disorders–like pain through regulating the expression and sensitization of PIEZO2
Science Advances · 2026
DOI: 10.1126/sciadv.aed1854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Qiaojuan Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Duke University, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Lysophospholipids, Signal Transduction, Receptors, Lysophosphatidic Acid, Temporomandibular Joint Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIDCR NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Temporomandibular disorders (TMD) pain is the most common orofacial pain with limited effective treatments. Here, we observed elevated lysophosphatidic acid (LPA), a bioactive lipid, in blood, trigeminal ganglion (TG), and peri-temporomandibular joint (TMJ) tissues in mouse models of TMD-like pain induced by TMJ inflammation or masseter muscle injury. Notably, LPA levels were also elevated in TMD patients’ blood and positively correlated with their pain intensity. LPA receptors (LPAR) 1 and 3 were expressed in mouse and human TG neurons and upregulated in TMD-like pain models. Inhibition or knockout of LPAR1 or LPAR3 attenuated TMD-like pain, while LPA injection into the TMJ or masseter muscle evoked pain. Furthermore, we demonstrated that LPA/LPAR signaling upregulates and sensitizes PIEZO2, a mechanosensitive ion channel, in TG neurons via extracellular signal-regulated kinase (ERK). Specific deletion or inhibition of PIEZO2 and suppression of ERK activation in TG neurons mitigated TMD-like pain. These findings suggest that LPA/LPAR signaling drives TMD-like pain via PIEZO2, offering potential therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Duke University, Durham, NC 27710, USA.
- Department of Biochemistry, Duke University, Durham, NC 27710, USA.
- Department of Anesthesiology, Duke University, Durham, NC 27710, USA.
- Orofacial Pain Clinic, Adams School of Dentistry, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA.
- Oral and Maxillofacial Surgery Clinic, Adams School of Dentistry, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA.
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
ORCID-Profile: Qiaojuan Zhang, Shanchun Su, Pengfei Liang, Yun Chen, Minseok Kim, Robert Baldi, Peng Wang, Fabiana C Dias, Minji Jang, Maria A Gonzalez Torres, Peifeng Lim, Jerold Chun, Farshid Guilak, Huanghe Yang, Wolfgang Liedtke, Andrea Nackley, Yong Chen
Förderung
- NIAMS NIH HHS
- NIDCR NIH HHS
- NINDS NIH HHS
- National Institutes of Health
Zitieren
APA
Zhang, Q., Su, S., Liang, P., Chen, Y., Kim, M., Baldi, R., Wang, P., Dias, F. C., Jang, M., Gonzalez Torres, M. A., Lim, P., Moreira, R. W. F., Chun, J., Guilak, F., Yang, H., Liedtke, W., Nackley, A., & Chen, Y. (2026). LPA/LPAR signaling drives temporomandibular disorders–like pain through regulating the expression and sensitization of PIEZO2. Science Advances. https://doi.org/10.1126/sciadv.aed1854
Vancouver
Zhang Q, Su S, Liang P, Chen Y, Kim M, Baldi R, et al. LPA/LPAR signaling drives temporomandibular disorders–like pain through regulating the expression and sensitization of PIEZO2. Science Advances. 2026. doi:10.1126/sciadv.aed1854
BibTeX
@article{Zhang2026,
author = {Zhang, Qiaojuan and Su, Shanchun and Liang, Pengfei and Chen, Yun and Kim, Minseok and Baldi, Robert and Wang, Peng and Dias, Fabiana C and Jang, Minji and Gonzalez Torres, Maria A and Lim, Peifeng and Moreira, Roger W F and Chun, Jerold and Guilak, Farshid and Yang, Huanghe and Liedtke, Wolfgang and Nackley, Andrea and Chen, Yong},
title = {LPA/LPAR signaling drives temporomandibular disorders–like pain through regulating the expression and sensitization of PIEZO2},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aed1854}
}
EUVIMED